Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Interim Management Statement

11 May 2011 07:00

RNS Number : 3201G
Genus PLC
11 May 2011
 



For immediate release 11 May 2011

 

 

GENUS plc

("Genus" or "the Company")

 

Interim Management Statement

 

Genus, a leading global animal genetics company, today publishes its interim management statement for the period from 1 January 2011 to 10 May 2011.

Market Conditions

In general the markets in which the Group operates have continued to improve, despite continuing high feed costs.

Pig prices have kept pace with the increases in feed costs in most countries and, as a result, customer profitability and the demand for Genus' products have been sustained. The exception to this has been in Europe where price increases have not been sufficient to restore profitability for pig producers and so the market has been relatively soft. In China, prices started to increase following the disease outbreaks last year and this has led to improved demand for genetics.

In bovines, milk prices have risen to better levels in most markets.

Trading Performance

Based on the results for the four months to 30 April 2011, Genus has continued to perform ahead of last year and in line with the Board's expectations.

In North America, the porcine business has continued to trade well with increased royalty income. In bovine, improved average selling prices and the benefit of cost reductions implemented in the first half of the year have improved profitability on sales at a similar level to last year. Demand has remained buoyant in Latin America resulting in increased volumes in both the bovine and porcine sectors.

In Europe, bovine performance improved as sales delayed from the first half of the year came through and dairy markets firmed. Porcine performance remained weak with reduced customer demand because of poor industry profitability.

In the Far East, strong growth in bovine volumes continued. Porcine performance began to improve as customer demand in China increased following a rise in pig prices.

Good progress has continued with the initiatives aimed at ensuring emerging market growth opportunities. Work to bring the new stud in Russia up to Genus' standards is nearing completion. A further 16 bulls have been shipped to China to meet the growing demand for progeny tested semen and strong sales growth is being achieved in India.

Financial Position

Net debt at 30 April 2011 of £85.4m was below the level at the same time last year (£94.0m), reflecting the group's underlying strong cash generation. It was, however, higher than at 31 December 2010, mainly because of the payment of the annual dividend and the £7.0m cash settlement cost of a US dollar swap transaction used to hedge the Group's US dollar net asset position.

The Group completed a refinancing in March 2011 to provide £135m of facilities on an unsecured basis through to 30 September 2015.

Outlook

Genus expects to continue to make good progress for the remainder of the year and that, as a result, the full year results to June 2011 will be in line with the Board's expectations.

Genus will announce its preliminary results for the year ending 30 June 2011 on 6 September 2011.

 

For further information please contact:-

 

Genus plc Tel: 01256 345970

 

Richard Wood, Chief Executive

John Worby, Finance Director

 

Buchanan Communications Tel: 0207 466 5000

 

Charles Ryland

Suzanne Brocks

Helen Chan

 

This announcement is available on the Genus website, www.genusplc.com

 

 

 

 

About Genus:

 

Genus plays a key role in the world's agricultural economy in its creation of advances in animal breeding through naturally applied biotechnology, helping farmers and food producers across the world to improve quality and increase output.

 

Genus provides superior natural animal genetics, enabling our global customers in the bovine and porcine supply chain to produce offspring in their herds with greater production efficiency, milk and meat output and quality. The challenge of meeting growing global demand for milk, pork and beef from the decreasing resources available for food production requires innovative solutions that Genus provides.

 

Genus' worldwide sales are made in seventy countries under the trade marks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production.

 

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals and the biotechnology used to improve them. Genus' global production and distribution network underpins our unique position in the world's growing agricultural markets.

 

Headquartered in Basingstoke, England, Genus is a FTSE250 company that operates in 30 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSSFAFLSFFSELI
Date   Source Headline
3rd Jul 20197:00 amRNSNotification of Major Holdings
1st Jul 20191:45 pmRNSTotal Voting Rights
18th Jun 20193:29 pmRNSNotification of Major Holdings
3rd Jun 20195:43 pmRNSTotal Voting Rights
24th May 20196:03 pmRNSDirector/PDMR Shareholding
16th May 20199:58 amRNSStrategic porcine collaboration in China
1st Apr 20191:54 pmRNSTotal Voting Rights
25th Mar 20197:00 amRNSGenus Chief Executive Transition
4th Mar 20193:11 pmRNSDirector/PDMR Shareholding
1st Mar 20192:00 pmRNSTotal Voting Rights
28th Feb 20197:00 amRNSInterim Results
1st Feb 20192:00 pmRNSBlock listing Interim Review
2nd Jan 20192:49 pmRNSTotal Voting Rights
11th Dec 20181:37 pmRNSDirector/PDMR Shareholding
7th Dec 20187:00 amRNSResult of placing to raise approximately £68m
6th Dec 20184:41 pmRNSProposed placing to raise approximately £68m
21st Nov 201812:00 pmRNSDirector Declaration
15th Nov 20184:00 pmRNSResult of AGM
15th Nov 20187:00 amRNSAGM Trading Update
1st Nov 20182:00 pmRNSTotal Voting Rights
12th Oct 20184:53 pmRNSAnnual Report and Annual General Meeting
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
12th Oct 20184:37 pmRNSDirector/PDMR Shareholding
1st Oct 20182:00 pmRNSTotal Voting Rights
24th Sep 20186:01 pmRNSAdditional Listing
24th Sep 20181:52 pmRNSNon-Executive Director Retirement
19th Sep 20183:36 pmRNSDirector/PDMR Shareholding
18th Sep 20185:21 pmRNSDirector/PDMR Shareholding
17th Sep 20185:27 pmRNSDirector/PDMR Shareholding
6th Sep 20187:00 amRNSPreliminary Results
1st Aug 20182:00 pmRNSBlock listing Interim Review
20th Jul 201811:56 amRNSHolding(s) in Company
11th Jul 20181:44 pmRNSHolding(s) in Company
9th Jul 20187:00 amRNSHolding(s) in Company
20th Jun 20187:00 amRNSCapital Markets Event
12th Jun 20182:42 pmRNSDirector/PDMR Shareholding
24th May 20187:00 amRNSBoard Appointment
18th May 20185:22 pmRNSDirector/PDMR Shareholding
1st May 20184:39 pmRNSTotal Voting Rights
12th Apr 20186:18 pmRNSDirector/PDMR Shareholding
16th Mar 20182:34 pmRNSDirector/PDMR Shareholding
5th Mar 20186:38 pmRNSDirector/PDMR Shareholding
1st Mar 201810:48 amRNSHolding(s) in Company
28th Feb 20187:00 amRNSInterim Results
1st Feb 20182:00 pmRNSBlock listing Interim Review
29th Dec 201711:51 amRNSDirector/PDMR Shareholding
22nd Dec 201711:27 amRNSDirector/PDMR Shareholding
13th Dec 20175:48 pmRNSDirector/PDMR Shareholding
8th Dec 20174:41 pmRNSDirector/PDMR Shareholding
1st Dec 20172:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.